Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,030 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
Goldstein D, Van Hazel G, Walpole E, Underhill C, Kotasek D, Michael M, Shapiro J, Davies T, Reece W, Harvey J, Spry N. Goldstein D, et al. Among authors: michael m. Br J Cancer. 2007 Aug 20;97(4):464-71. doi: 10.1038/sj.bjc.6603900. Epub 2007 Jul 24. Br J Cancer. 2007. PMID: 17653074 Free PMC article. Clinical Trial.
Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood.
Liu Z, Martin J, Orme L, Seddon B, Desai J, Nicholls W, Thomson D, Porter D, McCowage G, Underhill C, Cranswick N, Michael M, Zacharin M, Herschtal A, Sivasuthan J, Thomas DM. Liu Z, et al. Among authors: michael m. Cancer Chemother Pharmacol. 2018 Nov;82(5):887-898. doi: 10.1007/s00280-018-3683-8. Epub 2018 Sep 11. Cancer Chemother Pharmacol. 2018. PMID: 30206658
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.
Klein O, Kee D, Markman B, Michael M, Underhill C, Carlino MS, Jackett L, Lum C, Scott C, Nagrial A, Behren A, So JY, Palmer J, Cebon J. Klein O, et al. Among authors: michael m. Clin Cancer Res. 2020 Sep 1;26(17):4454-4459. doi: 10.1158/1078-0432.CCR-20-0621. Epub 2020 Jun 12. Clin Cancer Res. 2020. PMID: 32532787 Clinical Trial.
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.
Klein O, Kee D, Nagrial A, Markman B, Underhill C, Michael M, Jackett L, Lum C, Behren A, Palmer J, Tebbutt NC, Carlino MS, Cebon J. Klein O, et al. Among authors: michael m. JAMA Oncol. 2020 Sep 1;6(9):1405-1409. doi: 10.1001/jamaoncol.2020.2814. JAMA Oncol. 2020. PMID: 32729929 Free PMC article. Clinical Trial.
Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial.
Glewis S, Alexander M, Lingaratnam S, Lee B, Campbell I, Krishnasamy M, IJzerman M, Fagery M, Harris S, Georgiou C, Underhill C, Warren M, Campbell R, Martin J, Tie J, Michael M. Glewis S, et al. Among authors: michael m. Acta Oncol. 2022 Sep;61(9):1136-1139. doi: 10.1080/0284186X.2022.2109423. Epub 2022 Aug 16. Acta Oncol. 2022. PMID: 35972781 No abstract available.
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
Tan L, Tran B, Tie J, Markman B, Ananda S, Tebbutt NC, Michael M, Link E, Wong SQ, Chandrashekar S, Guinto J, Ritchie D, Koldej R, Solomon BJ, McArthur GA, Hicks RJ, Gibbs P, Dawson SJ, Desai J. Tan L, et al. Among authors: michael m. Clin Cancer Res. 2023 Mar 14;29(6):1017-1030. doi: 10.1158/1078-0432.CCR-22-3094. Clin Cancer Res. 2023. PMID: 36638198 Free PMC article. Clinical Trial.
1,030 results